The iQ Group Global named as one of Australia’s Top 5 Most Innovative Health Companies
The iQ Group Global is honoured to be recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine in its relentless pursuit to create the medicines of tomorrow. The iQ Group Global ranked #5 on the Health Industries list, from more than 800 nominated […]
The iQ Group Global supports excellence in diabetes research
The iQ Group Global continued its commitment to unearthing cutting edge research in biosciences by supporting the Diabetes Australia Research awards last month. The awards, presented at NSW Parliament House on July 19, honour the people and institutions behind the research contributing to the prevention, management and cure for all types of diabetes. Diabetes Australia […]
iQGG Recognised as Top 10 Diabetes Care Solutions Provider
The iQ Group Global has been recognised by Med Tech Outlook magazine as one of the Top 10 Diabetes Care Solutions Providers in 2019. The Saliva Glucose Biosensor is the world’s first non-invasive, saliva-based glucose test for diabetes management that measures glucose in saliva, not blood. With this world-first technology, our global mission is to […]
Federal Budget 2018: $1.3b plan to make Australia a medical technology leader
Last night’s 2018 Federal budget saw a raft of funding and exciting initiatives aimed at further supporting Australia’s position as a global medical technology leader. Here’s how: Supporting Medical Research A 21st Century Medical Industry Growth Plan will deliver $1.3 billion to support Australia as a global health industry leader in medical technology, biotechnology and pharmaceuticals […]
Farmaforce quarterly cash flow report shows continued sales excellence
FarmaForce Limited (ASX:FFC) has delivered more evidence of its continued growth as Australia’s premier healthcare contract sales organisation (CSO) with its latest ASX announcement, showing a 100% increase in sales in Q3 FY19 compared to Q3 FY18. With a 57% compound annual growth rate (CAGR) over the last four years, FarmaForce is significantly outperforming Australia’s […]
Biotech vs The Budget 2019-20 video
Last week, Treasurer Josh Frydenberg announced the Morrison government’s Budget for 2019-20, should they win the federal election in May. In a newly released video, The iQ Group Global’s Senior Economist Laurence Parker-Brown explains the crucial changes needed to activate a thriving biotech industry in Australia – and why the industry cannot rely on government […]
Saliva Glucose Biosensor in Medgadget
The Saliva Glucose Biosensor and The iQ Group Global are in the headlines again, this time featuring on the homepage of popular medical technologies news site Medgadget. Read the article here.
iQGG and Saliva Glucose Biosensor feature in Diagnostics World
The iQ Group Global appeared in Diagnostics World News today, a leading publication for emerging technologies in diagnostics. The article is a feature on the Saliva Glucose Biosensor, the world’s first saliva-based glucose test for diabetes management that measures glucose in saliva rather than blood. To read the article in full visit the website
iQGG In The Australian Financial Review
Dr George Syrmalis, Group CEO and Chairman of The iQ Group Global, is featured in The Australian Financial Review today. In the interview Dr Syrmalis discusses the evolution of biotech in China, outlines The Group’s plans to enter the Chinese market with the ground-breaking biosensor platform technology, and details the strategy behind The Group’s proposed […]
Dr George Syrmalis featured in CEO Magazine
Dr George Syrmalis, Group CEO of The iQ Group Global, is featured in the November edition of The CEO Magazine. In his interview ‘The Power of Practical Thinking’, Dr Syrmalis discusses his approach to leadership, outlines his vision for The Group’s future, and highlights the necessity for pragmatism in the biopharmaceutical industry. The article also […]